Suggested reading

Association of Human Whole Blood NAD+Contents With Aging

Yang et al 2022

Association of NAD+ levels with metabolic disease in a community-based study

Liu et al 2023

Blood NAD levels are reduced in very old patients hospitalized for heart failure

Breton et al 2020

Cold-stimulated brown adipose tissue activation is related to changes in serum metabolites relevant to NAD+ metabolism in humans

U-Din et al 2023

Dietary supplementation with NAD+-boosting compounds in humans: Current knowledge and future directions

Freeberg et al 2023

Elevation of NAD+ by nicotinamide riboside spares spinal cord tissue from injury and promotes locomotor recovery

Metcalfe et al 2023

Evaluation of potential aging biomarkers in healthy individuals: telomerase, AGEs, GDF11/15, sirtuin 1, NAD+, NLRP3, DNA/RNA damage, and klotho

Borsky et al 2023

Human ovarian aging is characterized by oxidative damage and mitochondrial dysfunction

Smits et al 2023

NAD+-boosting compounds enhance nitric oxide production and prevent oxidative stress in endothelial cells exposed to plasma from patients with COVID-19.

Freeberg et al 2023

NAD depletion mediates cytotoxicity in human neurons with autophagy deficiency

Sun et al. 2023

NAD+repletion with niacin counteracts cancer cachexia

Beltrà et al 2023

Niacin Cures Systemic NAD+ Deficiency and Improves Muscle Performance in Adult-Onset Mitochondrial Myopathy

Pirinen et al 2020

Nicotinamide enhances myelin production after demyelination through reduction of astrogliosis and microgliosis

Kaplanis et al 2023

Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study

Lapatto et al 2023

Preclinical characterization of pharmacological NAD+ boosting as a promising therapeutic approach in Rheumatoid Arthritis

Perez-Sanchez et al 2023

SARS-CoV-2 infection dysregulates NAD metabolism

Idazpanah et al 2023

The acute effect of different NAD+ precursors included in the combined metabolic activators

Li et al 2023

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson’s disease

Brakedal et al 2021

The Promise of Niacin in Neurology

Wuerch et al 2023